Every material Form 8-K BridgeBio Oncology Therapeutics, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BridgeBio Oncology Therapeutics said its Chief Medical and Development Officer, Yong Ben, gave notice of his resignation on October 30, 2026, effective January 8, 2027. The filing states the departure was not due to any disagreement with the company's operations, policies or practices, and it does not name a successor.
Yong Ben gave notice of resignation as Chief Medical and Development Officer on October 30, 2026.
Resignation takes effect January 8, 2027.
The company states the resignation was not due to any disagreement over operations, policies or practices.
BBOT released new Phase 1 data for BBO-8520 and said it will focus its capital on BBO-8520 plus pembrolizumab in second-line-plus KRAS G12C inhibitor-experienced lung cancer and on BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers. The attached corporate presentation says BBO-8520 in first-line NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment. For shareholders, the filing narrows the pipeline focus, and the company projects its $344.1 million in cash will fund operations into 2028.
BBO-8520 plus pembrolizumab showed a 75% objective response rate at the 500 mg once-daily dose and 53% across all dose levels (N=17) in the ONKORAS-101 study, with a June 1, 2026 data cutoff.
Cash, cash equivalents and marketable securities were $344.1 million as of June 30, 2026, which the company projects will fund operations into 2028.
BBO-11818 and BBO-10203 monotherapy data update is expected in Q4 2026; expanded BBO-8520 plus pembrolizumab data is expected in mid-2027.
The corporate presentation says BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer have been deprioritized, with no near-term plans for further investment.
BridgeBio Oncology Therapeutics (BBOT) reported a second-quarter 2026 net loss of $56.5 million, up from $28.4 million in the same quarter of 2025, as research and development and general and administrative expenses rose. As of June 30, 2026, the company had $344.1 million in cash, cash equivalents and marketable securities, which it says is expected to provide cash runway into 2028.
Net loss of $56.5 million, or $705.20 per share, for Q2 2026, versus $28.4 million, or $566.46 per share, for Q2 2025
R&D expenses rose to $49.2 million from $27.4 million, mainly from higher clinical trial and manufacturing costs for BBO-8520, BBO-11818 and BBO-10203
G&A expenses rose to $11.0 million from $2.7 million, including standalone operations, the de-SPAC transaction and one-time severance for former executives
Cash and marketable securities were $344.1 million at June 30, 2026, down from $425.5 million at December 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BridgeBio Oncology Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →